ROXALL Medizin GmbH

Address
Carl-Petersen-Strasse 4, Hamm-Nord

Sponsor Overview

assignment
9
sponsored trials
science
33
molecules
location_city
9
research centres
public
2
countries
person_search
14
investigators

Specializations

Allergic Rhinitis and Rhinoconjunctivitis

ROXALL Medizin GmbH focuses on moderate-to-severe allergic rhinitis and rhinoconjunctivitis linked to airborne allergens, with trials centered on symptom control and treatment tolerability in patients affected by seasonal and perennial disease patterns.

  • House dust mite allergy
  • Birch pollen allergy
  • Grass pollen allergy
  • Olive pollen allergy

The research portfolio includes both subcutaneous immunotherapy and sublingual immunotherapy approaches for upper-airway allergic disease.

Allergen Immunotherapy

The sponsor’s clinical activity is concentrated on allergen immunotherapy for respiratory allergy, with attention to treatment options designed to address specific sensitizations and improve allergic symptom burden.

  • Cluster immunotherapy
  • Sublingual immunotherapy
  • Subcutaneous immunotherapy
  • Allergen-specific treatment

Its studies examine multiple allergen sources, including pollen and mite-related triggers, across distinct therapeutic delivery routes.

Respiratory Allergy Symptom Management

Clinical research extends to outcomes relevant to day-to-day control of allergic symptoms, with emphasis on combined symptom and medication burden in patients with persistent respiratory allergy.

  • Combined Symptom and Medication Score
  • Benefit-risk balance
  • Tolerability
  • Allergic symptom relief

This area reflects interest in therapies for chronic nasal and ocular allergy manifestations associated with environmental exposure.

Seasonal and Perennial Aeroallergen Sensitization

The funded trials cover both seasonal allergic disease and perennial exposure-driven allergy, including sensitization to tree, grass, olive, and mite allergens.

  • Tree pollen sensitization
  • Grass pollen sensitization
  • Olive pollen sensitization
  • House dust mite sensitization

These studies address patient groups with sustained allergic symptoms over multiple years.

European Multicentre Allergy Research

The sponsor supports multicentre clinical research across Europe, with active trial sites in more than one country and a portfolio dedicated to allergic disease.

  • Multicentre allergy trials
  • Cross-country recruitment
  • Respiratory allergen studies
  • Specialist allergy sites

Its research activity is concentrated in patient populations with defined allergen-driven upper respiratory tract disease.

Sponsored Trials

Trial Name Country Status
Efficacy and Safety Evaluation of Phleum Pratense Pollen Extract Sublingual Immunotherapy in Moderate-to-Severe Grass Pollen-Induced Allergic Rhinitis PatientsGermany GermanyNot Recruiting
Efficacy and Safety Evaluation of Phleum Pratense Pollen Extract Sublingual Immunotherapy in Patients with Moderate-to-Severe Grass Pollen-Induced Allergic RhinitisGermany GermanyNot Recruiting
Efficacy and Safety Evaluation of Subcutaneous Cluster Immunotherapy with Allergenic Extract of Olea Europaea Pollen in Moderate-to-Severe Allergic RhinitisSpain SpainNot Recruiting
Efficacy and Safety Evaluation of Subcutaneous Cluster-Immunotherapy with Allergen Extract from Phleum pratense Pollen in Moderate-to-Severe Grass Pollen AllergyGermany GermanyNot Recruiting
Efficacy and Safety Evaluation of Subcutaneous Cluster-Immunotherapy with Birch Pollen Allergoid Glutaraldehyde Modified in Moderate-to-Severe Allergic RhinitisGermany GermanyNot Recruiting
Efficacy and Safety Evaluation of Subcutaneous Cluster-Immunotherapy with Dermatophagoides Pteronyssinus Allergoid in Moderate-to-Severe House Dust Mite AllergyGermany GermanySpain SpainNot Recruiting
Efficacy and Safety Evaluation of Sublingual Immunotherapy with Betula Pendula Pollen Extract in Patients with Birch Pollen-Induced Allergic RhinitisGermany GermanyNot Recruiting
Efficacy and Safety Evaluation of Sublingual Immunotherapy with Betula Pollen Extract in Patients with Moderate-to-Severe Birch Pollen-Induced Allergic RhinitisGermany GermanyNot Recruiting
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy. A prospective, international, randomized, double-blind, placebo-controlled, multicentre, phase II-III trial.Germany GermanySpain SpainNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
11
Exclusive Molecules
out of 33 total (33% not shared with other sponsors)

This sponsor works with 33 molecules, of which 11 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
67%
Return partnership rate
6 of 9 sites collaborated multiple times

This sponsor has worked with 9 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Immune System Diseases9 trials
    322 other sponsors

Partnered Research Centres

9 centres
location_city
assignment2
Complejo Hospitalario de Jaén
Address
Avda. del Ejército Español 10, 23007 Jaén
Learn morearrow_forward
location_city
assignment7
HNO Praxis Dresden Dr. med. Udo Schäfer
Address
Altmarkt 10A, 01067 Dresden
Learn morearrow_forward
location_city
assignment3
HNO-Praxis Dr. med. Udo Schäfer
Address
Altmarkt 10A, 01067 Dresden
Learn morearrow_forward
location_city
assignment49
Hospital General Universitario De Castellon
Address
Avenida De Benicasim S/n, 12004 Castellon
Learn morearrow_forward
location_city
assignment161
Hospital Universitario Donostia
Address
Pasealeku Doct. Begiristain 109, 20014 Donostia / San Sebastian
Learn morearrow_forward
location_city
assignment480
Hospital Universitario Hermanos Trias y Pujol. Institut Catalá d'Oncología (ICO)
Address
Carretera Canyet 1a Planta, 08916 Badalona
Learn morearrow_forward
Page 1 of 2

Want to get in touch with this sponsor?

Send a question and we'll pass it on to ROXALL Medizin GmbH.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.